Found 206 cc-cancer-center trials
A listing of cc-cancer-center medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
Patients with plasmablastic lymphoma are potential participants of this research trial. Patients with a type of B-cell non-Hodgkin lymphoma (NHL) will be invited from Penn Medicine practices. This research study is designed to test the safety of daratumumab, a drug added to the standard lymphoma treatment when given to individuals …
This phase II trial studies how well avelumab in combination with binimetinib, utomilumab, or anti-OX40 antibody PF-04518600 works in treating patients with triple negative breast cancer that is stage IV or is not able to be removed by surgery (unresectable) and has come back (recurrent). Immunotherapy with checkpoint inhibitors like …
An Open-Label, Multicenter, First-in-Human, Dose-Escalation Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas.
This is a Phase 1, multiple-dose, ascending dose-escalation and expansion study of XmAb22841, both as a monotherapy and in combination with pembrolizumab. The study is designed in 2 parts, Part A and Part B. Part A is a 3 + 3 dose escalation designed to assess both XmAb22841 administered as …
ASTX295 is a synthetic small molecule that acts as an antagonist of Murine Double Minute 2 (MDM2; human homolog also known as HDM2). Study ASTX295-01 is a study with ASTX295 in subjects who are refractory or have relapsed after treatment with standard of care therapies, or for whom standard life-prolonging …
This is a Phase I dose-escalation and dose-expansion study that will evaluate the safety, pharmacokinetics (PK), and preliminary activity of GDC-6036 in patients with advanced or metastatic solid tumors with a KRAS G12C mutation.
This is a randomized phase 2 open label study of sacituzumab govitecan +/- pembrolizumab for patients with PD-L1-negative (PD-L1-) metastatic triple negative breast cancer (TNBC), who have not received prior therapy for metastatic breast cancer and who have not received a prior PD-1/L1 inhibitor
A clinical trial to determine whether adding experimental agents to standard neoadjuvant paclitaxel (with or without trastuzumab), anthracycline, nad cyclosphosphamide increases the probability of pathologic complete response (pCR) over standard neoadjuvant chemotherapy for each biomarker signature established at trial entry, and to determine for each experimental agent used, the predictive …
The HER2 regulates cell growth and survival. This study will evaluate a new treatment using a potent Poly polymerase (PARP) inhibitor known as Niraparib. Niraparib will be combined with trastuzumab, a HER2-targeted agent, to evaluate the safety and tolerability in patients with metastatic HER2 positive breast cancer. It is anticipated …
This is a study to evaluate the efficacy and safety of Belzutifan monotherapy in participants with advanced pheochromocytoma/paraganglioma (PPGL) or pancreatic neuroendocrine tumor (pNET). The primary objective of the study is to evaluate the objective response rate (ORR) of belzutifan per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST …
